Company intelligence / Profile preview

AI Technology Group

Reno, Nevada, United States

Ownership: Private
Development stage: Other

Overview

AI Technology Group has signed a definitive agreement to acquire AVM Biotechnology. AVM is developing AVM0703, a small-molecule immunotherapy drug designed to reactivate the body's Reserve Immune System. The drug has been administered to 90 patients across Phase 1b/2 clinical trials, FDA Expanded Access, and Compassionate Use programs with over 250 total infusions. No safety signals have been observed in any treated subjects, even with repeat dosing up to 19 cycles. AVM0703 is currently in Phase 2 human trials for relapsed/refractory non-Hodgkin lymphoma.

Therapeutic areas: HematologyImmunologyEndocrinologyInfectious DiseasesOncology
Modalities: Small moleculeImmunotherapy
Industry: Biotech

Beyond the preview

Go deeper on AI Technology Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AI Technology Group.

Explore the full profile